05.01.21

Johnson & Johnson Vision Presents New Myopia, Cataract, Refractive, and Meibomian Gland Dysfunction Data at ARVO 2021

Source: Johnson & Johnson Vision

04.29.21

Lumenis Receives FDA Approval for Its IPL Device to Manage Dry Eye Disease and Launches OptiLight

Source: Lumenis

03.17.21

Hovione Completes Phase 2 Clinical Trial of First Minocycline Ophthalmic for Dry Eye Disease Associated With Inflamed MGD

Source: Hovione

03.17.21

New Study Finds Significant Improvements in DED Following Use of Eye Eco Tranquileyes XL and Tranquilvibes Hydrating Masks

Source: Eye Eco

03.03.21

Azura Ophthalmics Announces Positive Topline Results From Phase 2 Program of Investigational Treatment for MGD

Source: Azura Ophthalmics

01.19.21

Bausch + Lomb Completes Enrollment Of First Phase 3 Study For NOV03 (Perfluorohexyloctane)

Source: Bausch + Lomb

11.24.20

Report: Dry Eye Treatment Devices Market Size Worth $400.8 Million By 2027

Source: Grand View Research, Inc.

11.24.20

Bausch Health Initiates Second Phase 3 Study for Investigational Treatment for Dry Eye Disease Associated With MGD

Source: Bausch Health Companies Inc.

10.22.20

Azura Ophthalmics Raises $20 Million for Registration Studies for Treatment of Meibomian Gland Dysfunction

Source: Azura Ophthalmics

10.01.20

New Company TearRestore Launches Reusable Heat Packs to Target the Meibomian Glands

Source: TearRestore

View more stories